Compare Bristol-Myers Squibb Co (BMY) vs NetEase Inc (NTES) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs NetEase Inc — how do they compare? Bristol-Myers Squibb Co trades at $63.7 (market cap $129.94B), while NetEase Inc trades at $122 (market cap $82.75B). The key difference: Bristol-Myers Squibb Co is the larger of the two by market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BMY | NTES | |
|---|---|---|
Market Cap | $129.94B | $82.75B |
Sector | Health | Media |
52-Week High | $65.89 | $159.34 |
52-Week Low | $42.60 | $109.26 |
Enterprise Value | $163.92B | $59.05B |
Dividend Yield | 3.96% | 2.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.
BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.
NetEase (NTES) trades at $124.08, down 6.99% over the past 24 hours, with a P/E ratio of 16.31 and strong profitability metrics including a 29.84% net income margin. Recent earnings show mixed results with a Q1 2026 beat but Q3 and Q4 2025 misses. Technical indicators suggest a bullish trend with support at $126 and resistance at $129. The company maintains robust cash flow from operations of $50.74 billion in 2025 and recently announced a $0.72 dividend for H1 2026.
Outlook remains positive with 82% analyst buy ratings and a projected 34.7% upside potential. Key opportunities include international expansion and strong free cash flow generation, while risks involve competitive pressures in gaming and regulatory uncertainties in China. Revenue growth is steady, reaching $112.63 billion in 2025, supporting a solid fundamental base for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About NetEase Inc
NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →
